Editorial intelligence
UniPharma perspectives on pharmaceutical supply, access, sourcing, regulation, and active-ingredient developments, with evergreen reference pages collected in one place.
Latest coverage
An MHRA recall of Eaststone quetiapine oral suspension puts focus on traceability, pharmacy recall action, and alternative supply for unlicensed specials.
Read insightThe government’s response keeps all reimbursement reform proposals alive, with potential effects on Drug Tariff pricing, pharmacy cash flow and specials procurement in England.
Read insightMHRA seized almost 20 million doses of illegally traded medicines in 2025, raising the stakes for UK sourcing controls, online monitoring, and supply-chain compliance.
Read insightCDC has told TB programs to diversify suppliers, use inter-program loans, and consider stockpile access as rifampin shortages and local supply gaps persist.
Read insightFDA can ease some shortage pressures through expedited reviews, foreign sourcing and expiry extensions, but it cannot run the market or compel supply.
Read insightA UK Tier 3 shortage alert for cisplatin and carboplatin is pushing trusts to source unlicensed imports and tighten aseptic and QA controls.
Read insightFDA’s latest shortage guidance sharpens expectations on reporting, risk plans, and expedited reviews, with direct consequences for suppliers, buyers, and U.S. market access.
Read insightFDASIA reshaped how the FDA manages drug shortages, with earlier manufacturer reporting, public non-compliance letters, and faster mitigation routes during supply disruption.
Read insightThe UK has brought forward its MHRA-NICE aligned pathway, tightening the link between licensing and HTA and changing launch planning for pharma companies.
Read insightThe UK is putting EAMS into law, giving manufacturers and hospitals a clearer route for pre-approval access, evidence collection, and supply planning.
Read insightFrance’s early access medicine pathway is moving quickly, with HAS tightening criteria in ways that matter for launch planning, evidence strategy, and time to funded access.
Read insightBelzutifan’s Innovation Passport shows how the UK’s ILAP can shape evidence planning, regulator alignment, and earlier access strategy for innovative medicines.
Read insightEvergreen library
8 pages
Aspirin is tracked by UniPharma because changes in supply, manufacturing, regulation, or demand can affect sourcing and market decisions for pharma teams operating across Europe and the UK.
Open pageChlorphenamine is tracked by UniPharma because changes in supply, manufacturing, regulation, or demand can affect sourcing and market decisions for pharma teams operating across Europe and the UK.
Open pageMexiletine is tracked by UniPharma because changes in supply, manufacturing, regulation, or demand can affect sourcing and market decisions for pharma teams operating across Europe and the UK.
Open pageOncology is monitored by UniPharma because shifts in demand, reimbursement, regulation, competition, or supply priorities can reshape procurement and launch planning.
Open pageDrug shortage supplier is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.
Open pageEarly Access Medicine is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.
Open pageUnlicensed Medicine Supply is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.
Open pageUnlicensed Medicines is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.
Open pageContact us
Bring us the access challenge, the shortage pressure or the regulated logistics brief. We will turn it into a clean operating plan.